株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

子宮内膜症治療薬の予測およびR&D 2017-2027年:代表的な治療薬 (Lupron、Eligard、Zoladex、Depo-Provera、Visanne)・企業・主要国市場の予測と分析

Endometriosis Drug Forecasts and R&D 2017-2027: Forecasts and Analysis of Leading Endometriosis Drugs (Lupron, Eligard, Zoladex, Depo-Provera, Visanne), Companies and Key National Markets

発行 Visiongain Ltd 商品コード 351720
出版日 ページ情報 英文 146 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=156.59円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
子宮内膜症治療薬の予測およびR&D 2017-2027年:代表的な治療薬 (Lupron、Eligard、Zoladex、Depo-Provera、Visanne)・企業・主要国市場の予測と分析 Endometriosis Drug Forecasts and R&D 2017-2027: Forecasts and Analysis of Leading Endometriosis Drugs (Lupron, Eligard, Zoladex, Depo-Provera, Visanne), Companies and Key National Markets
出版日: 2017年08月07日 ページ情報: 英文 146 Pages
概要

世界の子宮内膜症向け治療薬の市場規模は、2027年には30億米ドル以上に達する見通しです。研究開発 (R&D) 活動の継続によるより効果的な治療薬の開発・上市や、疾患に対する社会的認識の広がりが、市場成長に大きく貢献する、と見られています。

当レポートでは、世界の子宮内膜症治療薬市場について調査し、世界市場全体の子宮内膜症治療薬の収益予測、主要企業の売上予測、主要国市場の予測、研究開発動向、および市場影響因子などについて、分析しています。

第1章 レポート概要

第2章 子宮内膜症とその治療法:概略

  • 子宮内膜症とは何か?
  • 子宮内膜症の発症件数・有病者数
  • 子宮内膜症の治療薬の市場
  • PEST分析:政治的・経済的・社会的・技術的要因
  • 市場成長促進因子・抑制因子
  • 子宮内膜症治療薬市場の将来展望 (今後12年間分)

第3章 主要国市場:将来展望 (今後11年間分)

  • 子宮内膜症治療:治療法別
    • ホルモン治療
    • 鎮痛剤
    • 外科治療

第4章 主要国の子宮内膜症市場 (今後11年間分)

  • 現在の市場情勢:米国が市場を独占
    • 今後の市場動向の見通し
  • 米国市場の動向見通し (今後11年間分)
  • 欧州主要5ヶ国 (EU5) 市場の動向見通し (今後11年間分)
    • 英国、フランス、ドイツ、スペイン、イタリア
  • 日本市場の動向見通し (今後11年間分)
  • 中国市場の動向見通し (今後11年間分)
  • インド市場の動向見通し (今後11年間分)
  • ブラジル市場の動向見通し (今後11年間分)
  • ロシア市場の動向見通し (今後11年間分)

第5章 世界の子宮内膜症市場の主要な治療薬

  • Lupron:代表的な子宮内膜症治療薬の一種
    • プロファイル
    • 市場収益額の実績値
    • 市場収益額の予測値 (今後11年間分)
  • Eligard:特許満了により直面する課題
  • Zoladex
  • Depo-Provera
  • Visanne:世界初の子宮内膜症向け経口薬 (Bayer)

第6章 子宮内膜症治療薬に関する研究開発 (R&D)

  • 業界内の協力とR&D活動
    • 子宮内膜症向け薬物治療に関する分析
  • 子宮内膜症向け治療薬の生産に従事している企業
  • AbbVie:子宮内膜症向け知慮薬の代表的メーカー
    • 企業概要、事業部門、近年の業績、パイプライン製品情報など
  • Pfizer
  • Bayer HealthCare:Visanneの売上高の急成長
  • AstraZeneca
  • アステラス製薬
  • 武田薬品工業
  • Repros Therapeutics Inc
  • Euroscreen S.A
  • キッセイ薬品
  • Addex Therapeutics

第7章 子宮内膜症治療薬市場の定性分析

  • SWOT分析:市場の将来展望
  • 市場の強み
    • 莫大かつ急速に増加しつつある高齢者人口
    • 多数の有望な候補薬
    • 二次的指標
  • 弱み
    • 疾患に対する認識の低さ
    • 医療費償還上の問題
    • より良い診断・治療法に対する需要
  • 機会
    • 有病者数の増加
    • 市場需要の拡大
    • 新たな作用機序・送達
  • 脅威
    • ジェネリック医薬品との競合
    • 政府の医療費抑制

第8章 調査結果・結論

  • 子宮内膜症治療薬市場の将来
  • 米国は引き続き国別の最大市場にとどまる
  • 子宮内膜症治療薬市場の動向

第9章 用語一覧・付録

目次
Product Code: PHA0221

Endometriosis - our new study reveals trends, R&D progress, and predicted revenues

Where is the Endometriosis market heading? If you are involved in this sector you must read this brand new report. Visiongain's report shows you the potential revenues streams to 2027, assessing data, trends, opportunities and business prospects there.

Discover How to Stay Ahead

Our 146-page report provides 108 tables, charts, clearly illustrating the data presented in this research. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted drug sales at overall world market regional level, as well as giving a deep insight into the pipeline for Endometriosis. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Endometriosis market. See how to exploit the opportunities.

Forecasts to 2027 and other analyses reveal the commercial prospects

  • In addition to revenue forecasting to 2027, our new study provides you with recent results, R&D overview, growth rates, and market shares.
  • You find original analyses, with business outlooks and developments.
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments.

Discover sales predictions for the world market and following Endometriosis Therapeutics:

  • Lupron
  • Eligard
  • Zoladex
  • Depo-Provera
  • Visanne

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 11 leading national markets:

  • The US
  • Germany
  • France
  • The UK
  • Spain
  • Italy
  • Japan
  • China
  • India
  • Brazil
  • Russia
  • RoW

The report also includes profiles and pipeline analysis for some of the leading companies in the Endometriosis market, with a focus on the Endometriosis segment of these companies' operations.

There will be growth in both established and in developing countries. Our analyses show that the both developed and developing markets, Germany, France and India in particular, will continue to achieve high revenue growth to 2027.

Leading companies and the potential for market growth

Overall world revenue for Endometriosis will surpass $3bn in 2027, our work calculates. This will be driven by the development of more effective drugs for the condition as well as raising awareness of Endometriosis over the forecast period

Our work identifies which organisations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How the Endometriosis Market report helps you

In summary, our 146-page report provides you with the following knowledge:

  • Revenue forecasts to 2027 for the Endometriosis market and 5 Leading Therapeutic Drugs for the condition - discover the industry's prospects, finding the most lucrative places for investments and revenues
  • Revenue forecasts to 2027 for 11 of the leading national markets - US, Germany, France, UK, Italy, Spain, Russia, Japan, China, India, Brazil
  • Discussion of what stimulates and restrains companies and the market
  • Prospects for established firms and those seeking to enter the market - including company profiles and R&D overviews for 10 companies involved in developing and manufacturing Endometriosis drugs

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else

With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain's study is for everybody needing commercial analyses for the Endometriosis market and leading companies. You will find data, trends and predictions.

Get our report today Endometriosis Drug Forecasts and R&D 2017-2027: Forecasts and Analysis of Leading Endometriosis Drugs (Lupron, Eligard, Zoladex, Depo-Provera, Visanne), Companies and Key National Markets. Avoid missing out - get our report now.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Endometriosis Drugs: Industry and Market Review
  • 1.2. Benefits of This Report
  • 1.3. How This Study Delivers
  • 1.4. Main Questions This Work Answers
  • 1.5. Who is This Report For?
  • 1.6. Methods of Research and Analysis
  • 1.7. Frequently Asked Questions (FAQ)
  • 1.8. Some Related Visiongain Reports
  • 1.9. About Visiongain

2. Introduction to Endometriosis and its Treatment

  • 2.1. What is Endometriosis?
  • 2.2. Incidence and Prevalence of Endometriosis
  • 2.3. The Endometriosis Drug Market, 2016
  • 2.4. PEST Analysis
    • 2.4.1. Political Factors
    • 2.4.2 Economic Factors
    • 2.4.3 Social Factors Affecting the Endometriosis Therapies Market
    • 2.4.4 Technological Developments in Endometriosis Treatment
  • 2.5 Market Growth Drivers and Restraints
  • 2.6 Outlook for the Endometriosis Drugs Market, 2016-2027

3. Leading National Markets: Outlooks, 2017-2027

  • 3.1 Endometriosis Treatment by Therapy
    • 3.1.1. Hormones
    • 3.1.2. Painkillers
    • 3.1.3. Surgical Treatment

4. Endometriosis Leading National Markets, 2017-2027

  • 4.1. Leading National Markets: The US Dominated in 2016
    • 4.1.1. What is The Future for Leading National Markets?
  • 4.2. The US Endometriosis Market, 2017 to 2027
  • 4.3. EU5 Endometriosis Market, 2017 to 2027
    • 4.3.1. The UK Endometriosis Market, 2017 to 2027
    • 4.3.2. French Endometriosis Market, 2017 to 2027: Steady Growth throughout the Forecast Period
    • 4.3.3. German Endometriosis Market, 2017 to 2027: Largest Market Share in European Union
    • 4.3.4. Spanish Endometriosis Market, 2017 to 2027
    • 4.3.5. Italian Endometriosis Market, 2017 to 2027
  • 4.4. Japanese Endometriosis Market, 2017 to 2027: Second Largest Market in the World
  • 4.5. Chinese Endometriosis Market, 2017 to 2027
  • 4.6. Indian Endometriosis Market, 2017 to 2027: Fast Growing Market
  • 4.7. Brazilian Endometriosis Market, 2017 to 2027
  • 4.8. Russian Endometriosis Market, 2017 to 2027

5. Leading Drugs in World Endometriosis Market, 2016

  • 5.1. Lupron: One of the Leading Endometriosis Drug in the Market
    • 5.1.1. Profile
    • 5.1.2. Lupron Historical Revenue
    • 5.1.3. Lupron Revenue Forecast, 2017-2027
  • 5.2. Eligard: Facing Challenges When Patent Expires
    • 5.2.1. Profile
    • 5.2.2. Eligard Historical Revenue
    • 5.2.3. Eligard Revenue Forecast, 2017-2027
  • 5.3. Zoladex
    • 5.3.1. Profile
    • 5.3.2. Zoladex Historical Revenue
    • 5.3.3. Zoladex Revenue Forecast, 2017-2027
  • 5.4. Depo-Provera
    • 5.4.1. Profile
    • 5.4.2. Depo-Provera Historical Revenue
    • 5.4.3. Depo-Provera Forecast, 2017 to 2027
  • 5.5. Visanne: First Oral Treatment for Endometriosis by Bayer
    • 5.5.1. Profile
    • 5.5.2. Visanne Historical Revenue
    • 5.5.3. Visanne Forecast, 2017 to 2027

6. Research and Development for Endometriosis Drugs

  • 6.1. Industry Collaboration and R&D Activities
    • 6.1.1. Investigational Drug Treatment for Endometriosis
  • 6.2. Companies Involved in Producing Drugs for Endometriosis
  • 6.3. AbbVie: Leading Producer of Endometriosis Drugs
    • 6.3.1. Company Description
    • 6.3.2. Business Segmentation
    • 6.3.3. AbbVie Revenue Performance, 2016
    • 6.3.4. Product in Pipeline: Elagolix, Oral Drug
  • 6.4. Pfizer
    • 6.4.1. Company Description
    • 6.4.2. Business Segmentation
    • 6.4.3. Pfizer Revenue Performance, 2016
  • 6.5. Bayer HealthCare: Visanne Showing Faster Growth in Revenue
    • 6.5.1. Company Description
    • 6.5.2. Business Segmentation
    • 6.5.3. Bayer HealthCare Revenue Performance, 2016
    • 6.5.4. Four Drug Candidates in Product Pipeline
  • 6.6. AstraZeneca
    • 6.6.1. Company Description
    • 6.6.2. Business Segmentation
    • 6.6.3. AstraZeneca Revenue Performance, 2016
  • 6.7. Astellas
    • 6.7.1. Company Description
    • 6.7.2. Business Segmentation
    • 6.7.3. ASP1707 an Oral Dosage Form: Product in Pipeline
  • 6.8. Takeda
    • 6.8.1. Company Description
    • 6.8.2. Business Segmentation
    • 6.8.3. Product in Pipeline: Relugolix- Oral Form
  • 6.9. Repros Therapeutics Inc
    • 6.9.1. Company Description
    • 6.9.2. Business Segmentation
    • 6.9.3. Product in Pipeline: Proellex in Phase II Trials
  • 6.10. Euroscreen S.A
    • 6.10.1. Company Description
    • 6.10.2. Business Segmentation
    • 6.10.3. Product in Pipeline: ESN364 Completes Enrolment in Phase II Trials
  • 6.11. Kissei Pharmaceutical
    • 6.11.1. Company Description
    • 6.11.2. Business Segmentation
    • 6.11.3. Product in Pipeline: KLH-2109 Exclusive Rights Given to ObsEva
  • 6.12. Addex Therapeutics
    • 6.12.1. Company Description
    • 6.12.2. Product in Pipeline

7. Qualitative Analysis of Endometriosis Drugs Market

  • 7.1. SWOT Analysis: Future Scope of The Market
  • 7.2. Strengths of The Market
    • 7.2.1. Vast, Expanding Ageing Population
    • 7.2.2. A Number of Promising Drug Candidates
    • 7.2.3. Secondary Indications
  • 7.3. Weaknesses
    • 7.3.1. Lack of Disease Awareness
    • 7.3.2. Reimbursement Issues
    • 7.3.3. Demand for Better Diagnosis and Treatment of Endometriosis
  • 7.4. Opportunities
    • 7.4.1. Rising Disease Prevalence
    • 7.4.2. Increased Demand in Market
    • 7.4.3. Novel Mechanisms and Delivery Methods
  • 7.5. Threats
    • 7.5.1. Competition from Generic Drugs
    • 7.5.2. Governments Limiting Healthcare Spending

8. Conclusions from the Research and Analysis

  • 8.1. Future of the Endometriosis Pharmaceuticals Market
  • 8.2. The US Will Remain The Largest National Market From 2017 to 2027
  • 8.3. Trends in the Endometriosis Treatments Market

9. Glossary

  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • Appendix A
  • About Visiongain
  • Appendix B
  • Visiongain Report Evaluation Form

List of Figures

  • Figure 2.1 Prevalence of Endometriosis in Women (in Millions), Leading Countries, 2016
  • Figure 2.2 Global Endometriosis Market Revenue Performance: Revenue ($bn), 2014-2016
  • Figure 2.3 Global Endometriosis Market: Drivers and Restraints, 2017-2027
  • Figure 2.4 Forecast Global Endometriosis Market: Revenue ($m), 2016-2027
  • Figure 4.1 Endometriosis Leading National Markets: Shares (%), 2016
  • Figure 4.2 Endometriosis Leading National Markets: Shares (%), 2016
  • Figure 4.3 Endometriosis Leading National Markets: Shares (%), 2022
  • Figure 4.4 Endometriosis Leading National Markets: Shares (%), 2027
  • Figure 4.5 The US Endometriosis Therapeutic Market Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 4.6 EU5 Endometriosis Therapeutic Market: Overall Revenue ($m), 2016-2027
  • Figure 4.7 EU5 Endometriosis Therapeutic Markets: National Shares (%), 2016, 2022 and 2027
  • Figure 4.8 EU5 Endometriosis Therapeutic Market Forecast: Revenue ($m) Breakdown by Countries, 2016-2027
  • Figure 4.9 The UK Endometriosis Therapeutic Market Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 4.10 French Endometriosis Therapeutic Market Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 4.11 German Endometriosis Therapeutic Market Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 4.12 Spanish Endometriosis Therapeutic Market Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 4.13 Italian Endometriosis Therapeutic Market Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 4.14 Japanese Endometriosis Therapeutic Market Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 4.15 Chinese Endometriosis Therapeutic Market Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 4.16 Indian Endometriosis Therapeutic Market Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 4.17 Brazilian Endometriosis Therapeutic Market Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 4.18 Russian Endometriosis Therapeutic Market Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 5.1 Endometriosis Drug Market: Revenue ($m) by Leading Drug, 2016
  • Figure 5.2 Endometriosis Drug Market: Revenue Share (%) by Leading Drugs, 2016
  • Figure 5.3 Endometriosis Drug Market: Revenue Share (%) by Leading Drugs, 2022
  • Figure 5.4 Endometriosis Drug Market: Revenue Share (%) by Leading Drugs, 2027
  • Figure 5.5 Lupron Revenue Segmentation: Revenue Share (%), 2016
  • Figure 5.6 Lupron Historical Revenue ($m), 2011-2016
  • Figure 5.7 Lupron Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 5.8 Eligard Revenue Segmentation: Revenue Share (%), 2016
  • Figure 5.9 Eligard Historical Revenue ($m), 2011-2016
  • Figure 5.10 Eligard Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 5.11 Zoladex Revenue Segmentation: Revenue Share (%), 2016
  • Figure 5.12 Zoladex Historical Revenue ($m), 2011-2016
  • Figure 5.13 Zoladex Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 5.14 Depo-Provera Revenue Segmentation: Revenue Share (%), 2016
  • Figure 5.15 Depo-Provera Historical Revenue ($m), 2011-2016
  • Figure 5.16 Depo-Provera Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 5.17 Visanne Historical Revenue ($m), 2011-2016
  • Figure 5.18 Visanne Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 6.1 AbbVie: Therapeutic Focus Areas, 2016
  • Figure 6.2 AbbVie: Revenue Share (%) for Lupron, 2016
  • Figure 6.3 Pfizer: Revenue ($m) by Business Segment, 2016
  • Figure 6.4 Pfizer: Revenue Share (%) by Business Segment, 2016
  • Figure 6.5 Bayer: Revenue Share (%) by Drugs, 2016
  • Figure 6.6 Bayer: Revenue Share ($m) by Drugs, 2016
  • Figure 6.7 AstraZeneca: Revenue ($m) by Segment, 2016
  • Figure 6.8 AstraZeneca: Revenue Share of Drugs (%), 2016
  • Figure 6.9 AstraZeneca: Revenue ($m) by Drugs, 2016

List of Tables

  • Table 1.1 Endometriosis Drug Sales: Leading National Markets, Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 1.2 Foreign Currency Exchange Rate to $US, 2016
  • Table 2.1 Prevalence of Endometriosis in Women: Leading Countries, 2016
  • Table 2.2 Global Endometriosis Market Revenue Performance: Revenue ($bn) and AGR (%), 2014-2016
  • Table 2.3 Political, Economic, Social and Technological Forces (PEST) Affecting Endometriosis Market, 2016
  • Table 2.4 Global Endometriosis Market: Revenues ($m), Annual Growth Rate (%), CAGR (%), 2016-2022
  • Table 2.5 Global Endometriosis Market: Revenues ($m), Annual Growth Rate (%), CAGR (%), 2022-2027
  • Table 4.1 Endometriosis Leading National Markets: Revenue ($m) and Market Share (%), 2016
  • Table 4.2 Endometriosis Leading National Markets Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 4.3 Market Share (%) and Revenue ($m) Comparison of the Leading Endometriosis Therapeutic National Markets, 2016, 2022 and 2027
  • Table 4.4 The US Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2022
  • Table 4.5 The US Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2022-2027
  • Table 4.6 EU5 Endometriosis Therapeutic Market Forecasts by Country: Revenue ($m), AGR (%), CAGR (%), 2016-2027
  • Table 4.7 The UK Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2022
  • Table 4.8 The UK Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2022-2027
  • Table 4.9 Historical and Future Profile of Payment Percentages
  • Table 4.10 French Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2022
  • Table 4.11 French Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2022-2027
  • Table 4.12 German Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2022
  • Table 4.13 German Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2022-2027
  • Table 4.14 Spanish Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2022
  • Table 4.14 Spanish Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2022-2027
  • Table 4.16 Italian Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2022
  • Table 4.17 Italian Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2022-2027
  • Table 4.18 Japanese Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2022
  • Table 4.19 Japanese Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2022-2027
  • Table 4.20 Chinese Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2022
  • Table 4.21 Chinese Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2022-2027
  • Table 4.22 Indian Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2022
  • Table 4.23 Indian Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2022-2027
  • Table 4.24 Brazilian Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2022
  • Table 4.25 Brazilian Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2022-2027
  • Table 4.26 Russian Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2022
  • Table 4.27 Russian Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2022-2027
  • Table 5.1 The Endometriosis Drug Market: Revenue ($m), Revenue Share (%) by Leading Drugs, 2016, 2022, 2027
  • Table 5.2 Endometriosis Market: Forecasts by Leading Drugs, Revenue ($m), AGR (%), CAGR (%), 2016-2027
  • Table 5.3 Lupron Revenue Segmentation: Revenue ($m), Revenue Share (%), 2016
  • Table 5.4 Lupron Historical Revenue ($m), Annual Growth (%) and CAGR (%), 2011-2016
  • Table 5.5 Lupron Forecast: Revenue ($m), Annual Growth (%) and CAGR (%), 2016-2027
  • Table 5.6 Eligard Revenue Segmentation: Revenue ($m), Revenue Share (%), 2016
  • Table 5.7 Eligard Historical Revenue ($m), Annual Growth (%) and CAGR (%), 2011-2016
  • Table 5.8 Eligard Forecast: Revenue ($m), Annual Growth (%) and CAGR (%), 2016-2027
  • Table 5.9 Zoladex Revenue Segmentation: Revenue ($m), Revenue Share (%), 2016
  • Table 5.10 Zoladex Historical Revenue ($m), Annual Growth (%) and CAGR (%), 2011-2016
  • Table 5.11 Zoladex Forecast: Revenue ($m), Annual Growth (%) and CAGR (%), 2016-2027
  • Table 5.12 Depo-Provera Revenue Segmentation: Revenue ($m), Revenue Share (%), 2016
  • Table 5.13 Depo-Provera Historical Revenue ($m), Annual Growth (%) and CAGR (%), 2011-2016
  • Table 5.14 Depo-Provera Forecast: Revenue ($m), Annual Growth (%) and CAGR (%), 2016-2027
  • Table 5.15 Visanne Historical Revenue ($m), Annual Growth (%) and CAGR (%), 2011-2016
  • Table 5.16 Visanne Forecast: Revenue ($m), Annual Growth (%) and CAGR (%), 2016-2027
  • Table 6.1 AbbVie: Drug Revenue ($m) and Change (%), 2015 and 2016
  • Table 6.2 AbbVie: Drug Revenue ($m) and Drug Revenue Share (%), 2016
  • Table 6.3 Pfizer: Revenue ($m) and Revenue Share (%) Based on Business Segment, 2016
  • Table 6.4 Bayer: Revenue ($m) and Revenue Share (%) Based on Business Segment, 2016
  • Table 6.5 Bayer: Drug Revenue ($m) and Drug Revenue Share (%), 2016
  • Table 6.6 AstraZeneca: Revenue ($m) and Revenue Share (%) Based on Business Segments, 2016
  • Table 6.7 List of Other Companies in the Endometriosis Market

Companies Listed

  • Abbott Laboratories
  • AbbVie
  • Ablynx NV
  • AC Immune SA
  • Active Biotech AB
  • Addex Therapeutics Ltd
  • Advanced Biological Laboratories SA
  • AEterna Zenaris
  • Agenus Schweiz AG
  • Agios Pharmaceuticals, Inc
  • Aileron Therapeutics, Inc
  • Akari Therapeutics Plc
  • Allergan Plc
  • Amanouchi Pharmaceutical Co
  • Amgen, Inc
  • Anacor Pharmaceuticals, Inc
  • AP Avadis Biotechnologies
  • Apeiron Biologics Ag
  • Apogenix GmbH
  • Aquinox Pharmaceuticals, Inc
  • ArQule, Inc
  • Array BioPharma, Inc
  • Astellas Pharma
  • AstraZeneca Plc
  • Atrix Laboratories
  • Bayer HealthCare
  • BeiGene Ltd
  • BioAtla LLC
  • Biogen, Inc
  • BioNTech AG
  • BioPorto A/S
  • Bio-Rad Laboratories, Inc
  • Celgene Corp
  • Celmatix Inc
  • CEL-SCI Corp
  • Cepheid
  • Cidara Therapeutics, Inc
  • Cogstate Ltd
  • Collplant Holdings Ltd
  • CRISPR Therapeutics AG
  • CTI BioPharma Corp
  • Cyprotex Plc
  • CytomX Therapeutics, Inc
  • Debiopharm International Sa
  • DelsiTech Ltd
  • Domain Therapeutics SA
  • Dongkook Pharmaceutical Co
  • ElexoPharm GmbH
  • Eli Lilly
  • Enanta Pharmaceuticals, Inc
  • EndoCeutics
  • Epizyme, Inc
  • Euroscreen S.A
  • Euthymics Bioscience Inc
  • Evotec AG
  • Florida Hospital
  • Fujisawa Pharmaceutical Co
  • Genentech, Inc
  • Genzyme Corporation
  • GlaxoSmithKline
  • Halozyme Therapeutics, Inc
  • HemoShear Therapeutics LLC
  • Highland Clinical Research
  • Hydra Biosciences Inc
  • Idera Pharmaceuticals, Inc
  • ImmunoGen, Inc
  • Immunomedics, Inc
  • Inc. Forendo Pharma Oy
  • Infinity Pharmaceuticals, Inc
  • Interleukin Genetics, Inc
  • Invivo Therapeutics Holdings Corp
  • Isifer AB
  • Jiangsu Kanion Pharmaceutical Co
  • Kissei Pharmaceutical
  • Lipicard Technologies Limited
  • Medigene AG
  • Meditrina Pharmaceuticals
  • Medivation, Inc
  • Mendel Biotechnology Inc
  • MorphoSys AG
  • Mylan NV
  • Myovant Sciences Ltd
  • Neurocrine Biosciences, Inc
  • NextCure Inc
  • ObsEva
  • OncoMed Pharmaceuticals, Inc
  • OncoTherapy Science, Inc
  • OPKO Health, Inc
  • Orphagen Pharmaceuticals
  • Peptidream Inc
  • Pfizer
  • Philogen
  • Philogen Spa
  • Portola Pharmaceuticals, Inc
  • PregLem SA
  • Probiodrug AG
  • pSivida Corp
  • Puma Biotechnology, Inc
  • Repros Therapeutics Inc
  • Roche
  • Sanofi
  • Schering AG
  • SK Chemicals Co
  • Takeda Pharmaceutical
  • Tolmar Therapeutics
  • ValiRX

Organisations Mentioned in This Report:

  • Aljazeera Hospital
  • Australian National University
  • Brigham and Women's Hospital
  • Centre for Endocrinology and Reproductive Medicine
  • Centre for Epidemiology and Health Research
  • Children's Hospital Boston
  • Food and Drug Administration (FDA)
  • Highland Clinical Research
  • Indian Brand Equity Foundation
  • Instituto de Investigacion Sanitaria La Fe
  • Jacksonville Centre for Clinical Research
  • Jiangsu Kanion Pharmaceutical Co
  • Ministry of Health, Labour, and Welfare (Japan)
  • National Health Service
  • National Institute for Clinical Excellence
  • National Institute of Health
  • Northwestern University
  • Northwestern University (Illinois)
  • Research OutSmarts Endometriosis
  • Turku University Hospital
  • University Hospital (Angers)
  • University Hospital (Mo)
  • University Hospital (Mo)
  • University Hospital (Rouen)
  • University of Arhus (Denmark)
  • University of Athens (Greece)
  • University of Cagliari (Italy)
  • University of Illinois
  • University of North Carolina School of Medicine (North Carolina)
  • University of Oxford
  • Women's Health Care at Frost Street
  • World Endometriosis Research Foundation
Back to Top